Mapping clinical and imaging factors that might predict cardiac events in breast cancer patients
- PMID: 40134591
- PMCID: PMC11932856
- DOI: 10.3389/fonc.2025.1552908
Mapping clinical and imaging factors that might predict cardiac events in breast cancer patients
Abstract
Background: Breast cancer is the most common in women, with a 90% overall survival at 5 years. Cardiotoxicity is a side effect that can modify their morbidity and mortality. Its low prevalence and long latency period have challenged the establishment of a strategy for early detection and prevention.
Objectives: To investigate the association between coronary artery calcium (CAC) in planning computed tomography (CT) and cardiac events.
Methods: Retrospective cohort of 873 breast cancer patients (460 right-side; 413 left-side) treated with radiotherapy (2013-2022). We extract the Hounsfield Unit to quantify the CAC degree from the heart structure in the planning CT. We used IBM-SPSS software (V 29.0 Armonk, NY) for the statistical analysis.
Results: After a median follow-up of 4.52 years (range: 2.42-6.22 years), the cardiac events incidence was 1.95% vs 5.1% in right and left breast cancer, respectively. The mean heart dose was higher in cases with cardiac events (6.74Gy vs 2.28Gy; p<0.01). CAC score>0 was detected in 32.76% of planning CT and was more frequent in the elderly and those with cardiovascular risk factors (p<0.01). Patients with cardiac events presented a CAC score>0 in 41.4% of cases. However, the overall survival in these patients did not differ from those without CAC (p=0.58).
Conclusions: Patients with cardiovascular risk factors and a mean cardiac dose greater than 5 Gy are at increased risk of cardiotoxicity and should be referred for Cardio-Oncology evaluation. The application of the CAC score in CT planning could be a valuable screening test that requires further study.
Keywords: breast cancer; cardiotoxicity; coronary artery calcium; planning CT; radiotherapy.
Copyright © 2025 Otero-Pla, Fuentes Raspall, Gallego Franco, Fernández Martínez, Gich Saladich, Jornet Sala, Lizondo Gisbert, Rojas Cordero, Isern Verdum and Sancho-Pardo.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Red Española de Registros de Cáncer . Estimaciones de la incidencia del cancer en España, 2024. Available at: https://redecan.org/es/noticias/37/redecan-publica-lasestimaciones-de-la... (Accessed 15 December 2024).
-
- Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. (1995) 333(22):1456–61. doi: 10.1056/NEJM199511303332203 - DOI - PubMed
-
- Overgaard M, Nielsen HM, Tramm T, Højris I, Grantzau TL, Alsner J, et al. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapyA 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial. Radiother Oncol. (2022) 170:4–13. doi: 10.1016/j.radonc.2022.03.008 - DOI - PubMed
-
- Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: Evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. (2017) 35(15):1641–9. doi: 10.1200/JCO.2016.72.0722 - DOI - PMC - PubMed
-
- Sardaro A, Petruzzelli MF, D'Errico MP, Grimaldi L, Pili G, Portaluri M. &Radiation-induced cardiac damage in early left breast cancer patients: risk 23 factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol. (2012) 103(2):133–42. doi: 10.1016/j.radonc.2012.02.008 - DOI - PubMed
LinkOut - more resources
Full Text Sources
